Sage Therapeutics (NASDAQ:SAGE – Get Rating) had its price objective reduced by Morgan Stanley from $53.00 to $50.00 in a research note issued to investors on Monday morning, Marketbeat reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.
Several other analysts have also weighed in on the company. Guggenheim lowered their price objective on Sage Therapeutics from $55.00 to $48.00 and set a buy rating for the company in a report on Friday, November 11th. HC Wainwright lowered their target price on Sage Therapeutics from $55.00 to $50.00 and set a neutral rating for the company in a report on Wednesday, November 9th. Stifel Nicolaus lowered their target price on Sage Therapeutics from $58.00 to $56.00 in a report on Tuesday, August 2nd. StockNews.com raised Sage Therapeutics from a sell rating to a hold rating in a report on Saturday, November 19th. Finally, Loop Capital started coverage on Sage Therapeutics in a report on Tuesday, November 1st. They set a hold rating and a $41.00 target price for the company. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of Hold and a consensus target price of $50.07.
Sage Therapeutics Stock Up 0.8 %
Shares of Sage Therapeutics stock opened at $37.45 on Monday. The firm has a market cap of $2.23 billion, a P/E ratio of -4.34 and a beta of 1.22. Sage Therapeutics has a fifty-two week low of $27.36 and a fifty-two week high of $45.74. The business has a 50-day moving average price of $37.67 and a 200 day moving average price of $36.68.
Institutional Investors Weigh In On Sage Therapeutics
About Sage Therapeutics
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on Sage Therapeutics (SAGE)
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.